> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Crescent Biopharma Has $289.4 Million To Back Cancer Trials Into 2028, It Expects
- URL: https://www.bullished.co/crescent-biopharma-has-289-4-million-to-back-cancer-trials-into-2028-it-expects-e4a4db3f/
- Published: 2026-11-12T22:07:06.000Z
- Updated: 2026-11-12T22:07:06.000Z
- Description: Patient dosing has begun for CR-002, with initial results expected in the second half of 2027.
- Author: Matteo Parrino
- Tags: SEC Filings, CBIO, Industry: Healthcare

[Crescent Biopharma](https://www.bullished.co/tag/cbio/), which is testing experimental cancer treatments, reported [$289.4 million](https://www.sec.gov/Archives/edgar/data/0001253689/000162828026073409/cbio-20261112.htm?ref=bullished.co) in quarter-end cash Thursday and expects it to cover operations into the second half of 2028\. Results accompanying its SEC filing put that funding alongside a newly started CR-002 trial and a series of expected cancer-drug readouts in 2027.

## July Financing Backs Rising Trial Costs

The unaudited cash balance at September 30 included [$133.4 million](https://www.sec.gov/Archives/edgar/data/0001253689/000162828026073409/pressrelease-livefile.htm?ref=bullished.co) of net proceeds from Crescent’s July public offering.

Third-quarter research spending rose to $34.3 million from $20.3 million a year earlier. Crescent attributed the increase to broader testing of CR-001 and preparations for the CR-002 study. Administrative expenses increased to $8.7 million from $5.5 million, which the company primarily tied to personnel costs, including stock-based pay, and professional services.

Net loss widened to $37.7 million from $24.6 million, although the loss per ordinary share narrowed to $0.90 from $1.27\. The weighted-average ordinary-share count used for that calculation increased to 39,056,224 from 16,540,771.

License revenue was $3.1 million, versus zero a year earlier. Crescent had approximately 44.1 million ordinary shares and share equivalents outstanding at quarter-end, including shares underlying pre-funded warrants and non-voting convertible preferred stock.

## CR-002 Moves Into Patient Testing

Crescent began [dosing patients](https://www.sec.gov/Archives/edgar/data/0001253689/000162828026073409/pressrelease-livefile.htm?ref=bullished.co) with CR-002 earlier this month in its global early-to-mid-stage trial. The treatment is an antibody-drug conjugate—an antibody carrying a toxin to cancer cells—that targets PD-L1.

The study will enroll people with advanced solid tumors in the United States, Europe and Asia Pacific. It includes lung, head and neck, gastrointestinal and gynecological cancers, with approximately 200 participants expected in the initial dose-testing and tumor-specific groups and room for further expansion.

Crescent expects the first CR-002 results in the second half of 2027, covering safety, how the drug behaves in the body and preliminary activity against tumors.

Its lead treatment, CR-001, is an antibody designed to bind both PD-1 and VEGF. Crescent’s [October pipeline update](https://www.sec.gov/Archives/edgar/data/0001253689/000162828026066006/cbio-20261015.htm?ref=bullished.co) outlined chemotherapy combinations and preparations for CR-002 testing. The company also announced in October that it had completed the initial dose-escalation portion of the CR-001 trial.

## 2027 Results Shape The Next Trials

Initial CR-001 results are expected in the [first quarter](https://www.globenewswire.com/news-release/2026/11/12/3402250/0/en/crescent-biopharma-reports-third-quarter-2026-financial-results-and-recent-business-highlights.html?ref=bullished.co) of 2027\. They will include preliminary tumor-response findings from up to 12 previously untreated non-small cell lung cancer patients, plus safety and other measurements from more than 125 patients across solid-tumor types.

Crescent CEO Joshua Brumm said the readouts would start with “monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients.” Chemotherapy-combination results from hundreds of patients are expected in mid-2027.

Kelun-Biotech, Crescent’s Chinese development partner with CR-001 rights in Greater China, is testing the drug with sacituzumab tirumotecan in mid-stage studies. Initial lung-cancer results are expected in mid-2027\. A combination trial pairing CR-001 with CR-003 is expected to begin in the first half of 2027.

Crescent holds CR-003 rights outside Greater China and plans to use findings from Kelun-Biotech’s ongoing Chinese trial to support global development. Early evidence of that drug’s activity is expected in the first quarter of 2027.

Crescent forecasts [more than 2,000](https://www.globenewswire.com/news-release/2026/11/12/3402250/0/en/crescent-biopharma-reports-third-quarter-2026-financial-results-and-recent-business-highlights.html?ref=bullished.co) patients dosed across its portfolio by mid-2027.

Crescent plans to start the first of multiple late-stage CR-001 trials in early 2028, depending on the results and further discussions with regulators.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — CRESCENT BIOPHARMA, INC. (CBIO)](https://www.sec.gov/Archives/edgar/data/0001253689/000162828026073409/cbio-20261112.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit pressrelease-livefile.htm — CRESCENT BIOPHARMA, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001253689/000162828026073409/pressrelease-livefile.htm?ref=bullished.co) — SEC EDGAR
- [Crescent Biopharma Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/12/3402250/0/en/crescent-biopharma-reports-third-quarter-2026-financial-results-and-recent-business-highlights.html?ref=bullished.co) — globenewswire.com
- [8-K filed 2026-10-15 — CRESCENT BIOPHARMA, INC. (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001253689/000162828026066006/cbio-20261015.htm?ref=bullished.co) — SEC EDGAR

### More on Crescent Biopharma

- [BlackRock Reports 5.6% Stake In Crescent Biopharma, 2,075,291 Shares](https://www.bullished.co/blackrock-reports-5-6-stake-in-crescent-biopharma-2-075-291-shares-9195049b/)
- [Crescent Biopharma Targets First-Quarter 2027 Data For CR-001 And Early-2028 Phase 3 Start](https://www.bullished.co/crescent-biopharma-targets-first-quarter-2027-data-for-cr-001-and-early-2028-phase-3-start-6153f396/)

[All Crescent Biopharma (CBIO) coverage →](https://www.bullished.co/tag/cbio/)